Boryung has announced the establishment of a new commercial entity, 'Boryung Pharma Solution,' dedicated to sales and marketing of prescription drugs. This move is part of a strategy to enhance expertise by dividing operations into distinct areas: production and research and development (R&D), sales and marketing, and space life sciences research.
On September 15, Boryung's board of directors approved the physical division necessary for the establishment of Boryung Pharma Solution. The new company is expected to launch in January 2027, following approval from shareholders at a meeting scheduled for October, with Boryung retaining 100% ownership.
As Boryung approaches its 70th anniversary next year, it has unveiled a new vision as a 'life sciences research infrastructure company.' The plan is to develop independent competitive infrastructures for production and R&D, commercial operations, and space life sciences research.
Boryung Pharma Solution will focus on commercial infrastructure, aiming to expand its product portfolio by continuously introducing blockbuster drugs from both domestic and international markets, while leveraging its expertise in sales and marketing to strengthen its position in the domestic market.
Boryung has set a goal for Boryung Pharma Solution to become 'the best commercial platform in South Korea,' targeting a market share of over 10% in the domestic pharmaceutical sector. The company stated that this would serve as a benchmark for determining its status as the 'overwhelming leader' in the domestic pharmaceutical industry.
The production and R&D division will serve as the foundation for Boryung's global essential medicines business. The company plans to evolve into a 'global essential pharma company' responsible for the entire lifecycle of essential medicines, from production to research and supply.
The space life sciences research infrastructure will be pursued as a strategic business, aiming to become a key gateway for domestic and international companies conducting research and development in the field of space life sciences.
Boryung has stated that the three business divisions will operate independently while remaining interconnected. Boryung Pharma Solution will serve as the foundation for domestic operations, while the production and R&D infrastructure will support global initiatives. The space life sciences research will be nurtured as a future growth driver.
As part of the physical division, personnel from the sales and marketing and management support sectors will transition to the new company without changes to their working conditions. Boryung aims to maintain employment and treatment during this transition while enhancing the expertise of its commercial organization.
Kim Jeong-kyun, CEO of Boryung, stated, "The launch of Boryung Pharma Solution is aimed at allowing each entity to focus on its strengths for greater growth. We will nurture it as a core growth pillar for Boryung."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.